Analysis of efficacy and indications of fenelidone tablets

Finerenone is a new type of non-steroidal selective aldosterone receptor antagonist (MRA), which has been widely studied for the treatment of patients with type 2 diabetes and chronic kidney disease (CKD). Such patients often suffer from persistent deterioration of renal function due to aldosterone-mediated inflammation and fibrotic processes, and nonelidone significantly slows the progression of the disease by blocking the action of aldosterone on mineralocorticoid receptors. Compared with traditional MRAs such as spironolactone and eplerenone, fenelinone has greater selectivity, lower risk of side effects, especially less impact on hyperkalemia, and is easier to use in combination with other antihypertensive drugs.

Clinically, fenelidone is clearly used to reducethe risk of decreased renal function, renal failure or adverse cardiovascular events in adult patients with type 2 diabetes and CKD. Its main indications include: patients with diabetic nephropathy, patients with persistent proteinuria, and high-risk groups with acceptable estimated glomerular filtration rate (eGFR) but elevated urinary albumin excretion rate (UACR). In large phase III trials (such as the FIDELIO-DKD and FIGARO-DKD studies), fenelidone has been proven to significantly reduce the incidence of renal function endpoints (such as eGFR decline, end-stage renal disease) and cardiovascular endpoints (such as heart failure hospitalization, cardiovascular death), and is particularly beneficial in delaying the progression of kidney disease.

In addition, the anti-inflammatory and anti-fibrotic effects of fenelidone also make it uniquely valuable in the systemic treatment of chronic kidney disease. Research shows that compared with traditional treatment, it has a more prominent protective effect on the cardiovascular system, can effectively reduce left ventricular hypertrophy and improve cardiac diastolic function, and also has potential benefits for patients with hypertension and heart failure.

It should be noted that although the side effects of fenelinone are relatively mild, blood potassium levels and renal function still need to be monitored during use, especially when used in combination withRAS inhibitors or potassium supplements.

Reference materials:https://www.kerendia.com/